Discovery of novel cGAS inhibitors based on natural flavonoids

• Published in: Bioorganic chemistry Vol. 140; p. 106802
• Main Authors: Li, Jiameng, Xiong, Muya, Liu, Jiayuan, Zhang, Fengping, Li, Minjun, Zhao, Wenfeng, Xu, Yechun
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2023
• Subjects: Crystal structure; Cyclic GMP-AMP synthase; Flavonoids; Inhibitor; Virtual screening; Virtual screening; Flavonoids; Inhibitor; Cyclic GMP-AMP synthase; Crystal structure
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2023.106802

[Display omitted] •Baicalein and baicalin were identified as new inhibitors of cGAS.•Crystal structures determination revealed different binding modes of baicalein and baicalin to cGAS.•A more potent cGAS inhibitor was yielded through virtual screening based on the crystal structures of cGAS in complex with the flavonoids. Cyclic GMP-AMP synthase (cGAS) plays an important role in the inflammatory response. It has been reported that aberrant activation of cGAS is associated with a variety of immune-mediated inflammatory disorders. The development of small molecule inhibitors of cGAS has been considered as a promising therapeutic strategy for the diseases. Flavonoids, a typical class of natural products, are known for their anti-inflammatory activities. Although cGAS is closely associated with inflammation, the potential effects of natural flavonoid compounds on cGAS have been rarely studied. Therefore, we screened an in-house natural flavonoid library by pyrophosphatase (PPiase) coupling assay and identified novel cGAS inhibitors baicalein and baicalin. Subsequently, crystal structures of the two natural flavonoids in complex with human cGAS were determined, which provide mechanistic insight into the anti-inflammatory activities of baicalein and baicalin at the molecular level. After that, a virtual screening based on the crystal structures of baicalein and baicalin in complex with human cGAS was performed. As a result, compound C20 was identified to inhibit both human and mouse cGAS with IC50 values of 2.28 and 1.44 μM, respectively, and its detailed interactions with human cGAS were further revealed by the X-ray crystal structure determination. These results demonstrate the potential of natural products used as hits in drug discovery and provide valuable hints for further development of cGAS inhibitors.